114P - Evaluation of pulmonary function parameters after moderate hypofractionated image-guided thoracic irradiation in locally advanced node-positive non-small cell lung cancer patients with very limited lung function

Locally advanced NSCLC

114P - Evaluation of pulmonary function parameters after moderate hypofractionated image-guided thoracic irradiation in locally advanced node-positive non-small cell lung cancer patients with very limited lung function

Authors

Farkhad Manapov (DE)
Olarn Roengvoraphoj (DE)
Julian Taugner (DE)
Maurice Dantes (DE)
Cherylina Wijaya (DE)
Claus Belka (DE)
Chukwuka Eze (DE)

Presenter

Farkhad Manapov (DE)

Abstract

Abstract

Background

To evaluate the changes in pulmonary function parameters (PFT) after moderate hypofractionated image-guided thoracic irradiation (Hypo-IGRT) in locally advanced node-positive non-small cell lung cancer patients with very limited lung function.

Methods

PFT was measured in 8 patients with NSCLC UICC stage IIIA, IIIB and IIIC (UICC 8^th Edition) and very limited PFT (FEV1 ≤ 1 L and/or DLCO ≤ 40% and/or long-term oxygen therapy) prior to as well as 3 and 6 months after Hypo-IGRT. Vital capacity (VC), forced expiratory volume in 1s (FEV1), and single-breath diffusing capacity of the lung for CO (DLCO-SB) as PFT parameters were analyzed. Hypo-IGRT was delivered to a total dose of 45 Gy (ICRU) in 15 fractions under daily image-guidance.

Results

Eight patients (5 men/3 women) were treated with Hypo-IGRT. The median follow-up was 20 months. COPD GOLD III and IV was diagnosed in 2 (25%) and 4(50%) patients, respectively. Five (63%) patients were on long-term oxygen treatment. The median initial VC, FEV1 and DLCO-SB was 1.69L/64.8% predicted (range: 1.36–2.66/33–80%), 1L/39.4% predicted (range: 0.78–1.26/28–60%) and 33.3% (range: 13.3–54), respectively. The median value for VC, FEV1 and DLCO-SB 3 months after Hypo-IGRT was 2.05L/56.35% predicted (range: 1.34–2.33/47–81.5%), 1.08L/47.5% predicted (range: 0.74–1.60/30.8–59.59%) and 38.55% (range: 24–68), respectively. At 6 months post-treatment, the mean value for VC, FEV1 and DLCO-SB was 1.64L/66% predicted (range: 1.41–2.79/35.5–75.5%), 1.0L/47% predicted (range: 0.65–1.28/24.5–54.10%) and 31% (range: 27–43%), respectively. The estimated median overall survival (OS) was not reached for the entire cohort.

Conclusions

No significant decrease in all tested parameters was found until 6 months after Hypo-IGRT. In this small study, Hypo-IGRT was safely delivered in locally advanced node-positive NSCLC patients with very limited lung function who were not suitable candidates for conventional treatment.